Escitalopram Oxalate 10 mg Tablets

Adult administration

The safety of doses exceeding 20mg per day has not been established. This medicine is administered once daily, in the morning or evening, without regard to meals. 1) Adults (1) Major depressive disorder: The usual dose is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. If the dose of this medicine is to be increased to 20mg, it should be increased at intervals of at least 1 week. In general, 2-4 weeks are required for antidepressant effects to become apparent. Even after symptoms have resolved, drug treatment for at least 6 months is required to ensure a therapeutic effect. (2) Panic disorder with or without agoraphobia: The recommended initial dose is 5mg per day for 1 week, followed by an increase to 10mg per day. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. The maximum effect appears after approximately 3 months. The safety and efficacy of long-term administration of this medicine for more than 10 weeks in the treatment of panic disorder have not been systematically studied. The physician should periodically reevaluate each patient to determine the need for continued treatment. (3) Social anxiety disorder: The usual dose is 10mg once daily. In general, 2-4 weeks are required for symptoms to improve. Thereafter, depending on the patient's response, the dose may be reduced to 5mg per day or increased to a maximum of 20mg per day. Social anxiety disorder is a condition with a chronic course, and continued treatment for 12 weeks is recommended to ensure a therapeutic effect. Long-term treatment in patients who responded was studied for 6 months, and should be considered for each patient to prevent relapse. The usefulness of long-term treatment should be reassessed regularly. (4) Generalized anxiety disorder: The initial dose is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day after at least 1 week of treatment. A long-term treatment study was conducted in patients who responded to 12 weeks of open-label treatment, in which 20mg per day was administered for at least 6 months. The physician should regularly reevaluate the usefulness of long-term treatment with this medicine for each patient. (5) Obsessive-compulsive disorder: The usual dose is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. A long-term treatment study was conducted in patients who responded to 16 weeks of open-label treatment, in which 10mg or 20mg per day was administered for at least 24 weeks. Obsessive-compulsive disorder is a chronic condition; treatment should be continued for a sufficient period to ensure recovery of symptoms. During long-term administration of this medicine, the usefulness and dose for each patient should be reassessed regularly. 2) Patients with renal impairment No dosage adjustment is necessary for patients with mild or moderate renal impairment. Caution should be exercised in patients with severe renal impairment (CLCR < 30㎖/min). 3) Patients with hepatic impairment An initial dose of 5mg per day for the first 2 weeks is recommended. Depending on the patient's response, the dose may be increased to 10mg per day. 4) Discontinuation of treatment When discontinuing this medicine, the dose should be gradually reduced over at least 1-2 weeks to avoid the possibility of withdrawal symptoms. 5) Switching from MAO inhibitors used to treat psychiatric disorders When discontinuing an MAO inhibitor used to treat psychiatric disorders and starting treatment with this medicine, an interval of at least 14 days must be allowed. Conversely, when starting an MAO inhibitor to treat psychiatric disorders, at least 14 days must have elapsed after discontinuing this medicine. 6) Other MAO inhibitors, such as linezolid or methylene blue Patients receiving linezolid or intravenous methylene blue should not start this medicine because of the increased risk of serotonin syndrome. For patients who require treatment for a more urgent psychiatric condition, including hospitalization and other interventional procedures, administration should be considered. It may be necessary to urgently administer linezolid or intravenous methylene blue to a patient already receiving this medicine. If no alternative to linezolid or intravenous methylene blue is available and the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome for a particular patient, this medicine may be discontinued immediately and linezolid or intravenous methylene blue administered. The patient should be monitored for symptoms of serotonin syndrome for 2 weeks after administration of linezolid or intravenous methylene blue, or until 24 hours after the last dose, whichever occurs first. Treatment with this medicine may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with administration of methylene blue by non-intravenous routes (oral tablets or local injection), or with intravenous administration of this medicine at a dose of 1mg/kg or less, is unclear.

This drug is an antidepressant used for the treatment of psychiatric disorders such as major depression. Particularly among young patients aged 18 to 24, there may be an increased risk of suicidal thoughts or behavior during treatment, necessitating careful judgment and continuous monitoring by the physician. This drug should not be taken in combination with certain medications, particularly MAO inhibitors, pimoxetine, or drugs that prolong QT interval, as serious side effects may occur; it is essential to consult a doctor. Patients with glaucoma or a history of glaucoma should use this medication cautiously, as it may increase eye pressure. During the initial 1-2 weeks of treatment, various side effects such as anxiety, insomnia, headaches, nausea, and fatigue may occur, but most of these symptoms will alleviate over time. This medication may affect blood coagulation, so patients at risk of bleeding or those on anticoagulants should use it with caution. Pregnant or breastfeeding women should consult their doctor, as this medication may affect the fetus or newborn. Abrupt cessation of the medication may result in withdrawal symptoms such as dizziness, sleep disturbances, and anxiety, therefore, the dosage should be reduced gradually. Elderly patients are advised to start with a lower dose and increase it with caution. While this medication is known not to affect driving or machinery operation, caution may be required depending on the individual. In case of overdose, there may be issues affecting the central nervous system, gastrointestinal tract, and cardiovascular system, requiring immediate medical attention. This medication is not recommended for children and adolescents as its safety and efficacy have not been established.

Thrombocytopenia, anaphylactic reaction, inappropriate secretion of antidiuretic hormone, hyperprolactinemia, decreased appetite, increased appetite, weight gain, weight loss, hyponatremia, anorexia, anxiety, restlessness, abnormal dreams, decreased libido, sexual dysfunction, bruxism, agitation, hyperexcitability, panic attack, confusion, aggression, depersonalization, hallucination, mania, suicidal ideation, suicidal behavior, insomnia, drowsiness, dizziness, altered perception, tremor, taste disorder, sleep disorder, syncope, serotonin syndrome, movement disorder, exercise intolerance, convulsion, psychomotor agitation, akathisia, mydriasis, visual impairment, tinnitus, tachycardia, bradycardia, QT interval prolongation on ECG, polymorphic ventricular tachycardia, ventricular arrhythmia, orthostatic hypotension, sinusitis, yawning, nosebleed, nausea, diarrhea, constipation, vomiting, dry mouth, gastrointestinal bleeding, hepatitis, abnormal liver function tests, increased sweating, urticaria, hair loss, rash, itching, petechiae, angioedema, arthralgia, myalgia, rhabdomyolysis, urinary retention, ejaculation disorder, erectile dysfunction, uterine bleeding, menorrhagia, galactorrhea, postpartum hemorrhage, fatigue, fever, edema, headache, xerostomia, abdominal pain, dyspepsia, enteritis, sensory disturbances, cough, asthma, dyspnea, fracture, palpitations, hypertension, paresis, extrapyramidal disorder, migraine, chest pain, increased urination, tremors, dry mouth, sedation, heartburn, anxiety, visual hallucinations, sexual dysfunction, decreased libido, anorexia, hallucination, asthma, dyspnea, fracture, arthralgia, hypertension, dizziness, sensory disturbances, paresis, extrapyramidal disorder, migraine, drowsiness, aggressive reaction, decreased libido, anorexia, hallucination, cough, asthma, dyspnea, weight gain, chest pain, fever, fracture, arthralgia, sexual dysfunction, palpitations, hypertension, nausea, constipation, xerostomia, abdominal pain, vomiting, dyspepsia, enteritis, diarrhea, headache, dizziness, sensory disturbances, paresis, extrapyramidal disorder, migraine, drowsiness, insomnia, aggressive reaction, decreased libido, anorexia, hallucination, cough, asthma, dyspnea, weight gain, chest pain, fever, fracture, arthralgia, sexual dysfunction, palpitations, hypertension, nausea, headache, dizziness, drowsiness, gastrointestinal discomfort, heartburn, sedation, dry mouth, decreased libido, decreased appetite, xerostomia, dyspepsia, sweating, increased urination, sexual dysfunction, tremors, weight gain, abdominal discomfort, anxiety, insomnia, visual hallucinations, headache, increased urination, dizziness, drowsiness, nausea, sleep disorder, anxiety, tremor, confusion, sweating, headache, diarrhea, palpitations

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature. Proper storage will help retain the medication's effectiveness and safety over time.

Appearance

White oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle